Citeline, a Norstella company

The new indication for ocular myasthenia gravis would target about 7,000 patients and provide another growth opportunity for the blockbuster FcRn inhibitor.

The latest round of MDUFA VI negotiations discussed different perspectives between the FDA and industry on TAP 2.0 and the agency’s proposals for enhancing the program.

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Medtronic plans to retain about 90% of the newly standalone MiniMed. While MiniMed’s 2025 revenues totaled $2.7bn, the company still posted a net loss amid strong competition from Abbott and Dexcom and recently announced more than six dozen layoffs at its California plant.

Amid a wider domestic market downturn, Beijing Health Guard’s three Phase III trials for two of its HPV vaccine candidates were suspended in January and February due to overdue payments to sites.

Sichuan Biokin Pharmaceutical’s iza-bren hit the co-primary endpoints of OS and PFS in a Phase III clinical study in Chinese patients with triple-negative breast cancer in the second and later-line settings.

2026 has already seen several major new funding rounds for Chinese biopharma ventures, including a $70m financing for CAR-T specialist Oricell and a $40m Angel round for ADC specialist Tosun.

Chinese company expands its amylin-targeting portfolio in obesity with fast-paced plans for progressing clinical trials in the US and finding partners.